- Home
- IFRX vs RMBI Comparison
IFRX vs RMBI Comparison
Compare IFRX & RMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- RMBI
- Stock Information
- Founded
- IFRX 2007
- RMBI 1887
- Country
- IFRX Germany
- RMBI United States
- Employees
- IFRX N/A
- RMBI N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- RMBI Major Banks
- Sector
- IFRX Health Care
- RMBI Finance
- Exchange
- IFRX Nasdaq
- RMBI Nasdaq
- Market Cap
- IFRX 143.7M
- RMBI 134.9M
- IPO Year
- IFRX 2017
- RMBI 2019
- Fundamental
- Price
- IFRX $2.47
- RMBI $13.42
- Analyst Decision
- IFRX Strong Buy
- RMBI
- Analyst Count
- IFRX 1
- RMBI 0
- Target Price
- IFRX $8.00
- RMBI N/A
- AVG Volume (30 Days)
- IFRX 174.5K
- RMBI 15.7K
- Earning Date
- IFRX 11-08-2024
- RMBI 01-31-2025
- Dividend Yield
- IFRX N/A
- RMBI 4.25%
- EPS Growth
- IFRX N/A
- RMBI N/A
- EPS
- IFRX N/A
- RMBI 0.87
- Revenue
- IFRX $187,930.00
- RMBI $42,258,740.00
- Revenue This Year
- IFRX $392.79
- RMBI N/A
- Revenue Next Year
- IFRX $156.76
- RMBI N/A
- P/E Ratio
- IFRX N/A
- RMBI $15.18
- Revenue Growth
- IFRX 177.12
- RMBI N/A
- 52 Week Low
- IFRX $1.17
- RMBI $10.11
- 52 Week High
- IFRX $2.82
- RMBI $15.15
- Technical
- Relative Strength Index (RSI)
- IFRX 53.59
- RMBI 49.56
- Support Level
- IFRX $2.16
- RMBI $12.26
- Resistance Level
- IFRX $2.65
- RMBI $13.01
- Average True Range (ATR)
- IFRX 0.23
- RMBI 0.60
- MACD
- IFRX -0.01
- RMBI -0.00
- Stochastic Oscillator
- IFRX 52.54
- RMBI 62.75
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.